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Inhibition of in vivo proliferation of androgen.
independent prostate cancers by an antagonist
of growth hormone-releasing hormone
A Jungwirth*, AV Schally, J Pinski, G Halmos, K Groot, P Armatis and M Vadillo-Buenfil
Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and Department of Medicine, Tulane University School of Medicine,
New Orleans, LA, USA
Summary Tumour-inhibitory effects of a new antagonist of growth hormone-releasing hormone (GH-RH), MZ-4-71, were evaluated in nude
mice bearing androgen-independent human prostate cancer cell lines DU-145 and PC-3 and in Copenhagen rats implanted with Dunning
R-3327 AT-1 prostatic adenocarcinoma. After 6 weeks of therapy, the tumour volume in nude mice with DU-145 prostate cancers treated with
40 ,ug day-' MZ-4-71 was significantly decreased to 37± 13 mm3 (P < 0.01) compared with controls that measured 194 ± 35 mm3. A similar
inhibition of tumour growth was obtained in nude mice bearing PC-3 cancers, in which the treatment with MZ-4-71 for 4 weeks diminished the
tumour volume to 1 19 ± 35 mm3 compared with 397± 115 mm3 forcontrol animals. Therapy with MZ-4-71 also significantly decreased weights
of PC-3 and DU-145 tumours and increased tumour doubling time. Serum levels of GH and IGF-I were significantly decreased in animals
treated with GH-RH antagonist. In PC-3 tumour tissue, the levels of IGF-I and IGF-II were reduced to non-detectable values after therapy
with MZ-4-71. The growth of Dunning R-3327 AT-1 tumours in rats was also significantly inhibited after 3 weeks of treatment with
100 gg of MZ-4-71 day-' i.p. as shown by a reduction in tumour volume and weight (both P-values < 0.05). Specific high-affinity binding sites
for IGF-I were found on the membranes of DU-145, PC-3 and Dunning R-3327 AT-1 tumours. Our results indicate that GH-RH antagonist
MZ-4-71 suppresses growth of PC-3, DU-145 and Dunning AT-I androgen-independent prostate cancers, through diminution of GH release
and the resulting decrease in the secretion of hepatic IGF-I, or through mechanisms involving a lowering of tumour IGF-I levels and possibly
an inhibition of tumour IGF-I and IGF-Il production. GH-RH antagonists could be considered for further development for the therapy of
prostate cancer, especially after the relapse.
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Carcinoma of the prostate is the most common malignant tumour
in men. It is expected that in 1996 approximately 317 000 new
cases ofprostate cancer will be diagnosed in the US and that about
41 000 deaths will occur from this disease (Parker et al, 1996). In
spite ofrefinements in surgical techniques (Walsh et al, 1994) and
improvement of clinical outcome after radiotherapy (Garnick,
1993), many patients experience a recurrence. According to
Lu-Yao et al (1996), 34.9% ofpatients studied afterradical prosta-
tectomy needed additional cancer therapy within 5 years ofinitial
surgery. In addition to these highly selectedpatients with clinically
localized prostate cancer at initial presentation, there is a large
group of men with advanced stages of the disease at the time of
primary diagnosis. Medical or surgical castration is the only estab-
lished therapy for local recurrence or advanced prostate cancer
(Schally et al, 1990) with an effective first-line response rate of
70-80% (Sharifi et al, 1990). However, all hormonal therapies
aimed at androgen deprivation can only provide a remission, and
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most patients with advanced prostatic carcinoma will relapse in
18-36 months. The suppression of androgen-independent prostate
cancer is a major oncological challenge, and new therapeutic
approaches must be developed.
The PC-3 prostate cancercell line was originally isolated from a
metastasis of a human prostatic adenocarcinoma to bone (Kaighn
et al, 1979). PC-3 cells show a reduced dependence upon serum
for growth and cannot be stimulated by androgens (Kaighn et al,
1979). The DU-145 cell line, derived from a human prostate
adenocarcinoma metastatic to the brain is also androgen indepen-
dent (Stone et al, 1978). These two cell lines can be xenografted
into nude mice. Dunning R 3327 AT-1, a subline derived from the
rat Dunning prostate cancer, is an anaplastic, hormone-insensitive
tumour, transplantable into rats (Isaacs et al, 1978). PC-3, DU-145
andDunning R-3327 AT-I cell lines are valuable models forinves-
tigating biological tumour behaviour and the effect of new anti-
cancer drugs on androgen-independent prostate carcinoma.
The prostate is a hormone-sensitive organ, primarily under the
control ofthe pituitary-gonadal axis (Schally et al, 1990; Reubi et
al, 1995). However, some regulatory factors other than androgens
have been identified, among them hormones, such as luteinizing
hormone-releasing hormone (LH-RH), GH, somatostatin and
bombesin-like peptides and growth factors, including epidermal
growth factor(EGF), transforminggrowthfactors-aand-P (TGF-a,
TGF-,3), IGF-I and IGF-II (Davies and Eaton, 1991; Schally et al,
1990; Reubi et al, 1995; Angelloz-Nicoud and Binoux, 1995;
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Reiter et al, 1995). These substances can directly or indirectly
regulate the function and growth of the prostate, especially after
malignant transformation. Synthesis of IGF-1 is induced primarily
by GH but, in addition, growth factors like EGF and proto-onco-
genes like c-myb may be involved (Pietrzkowski et al, 1993). IGF-
I is synthesized and secreted mostly by the liver, but also by other
tissues, such as lung and kidney (Froesch et al, 1985). Various
cancer cells are likewise able to produce and secrete insulin-like
growth factors (Macaulay, 1992), among them PC-3 and DU-145
prostate cancer cell lines (Pietrzkowski et al, 1993). Type I IGF
receptors (IGFRs) have been shown on membranes ofDU-145 and
PC-3 cells (Pietrzkowski et al, 1993). Furthermore, there is some
evidence that IGF might be responsible for the progression of
prostate cancer in the advanced stages. Consequently, the blocking
ofthe GH-IGF axis might lead to improvement in the treatment of
advanced, androgen-independent prostate cancer.
Recently, various potent GH-RH antagonists have been synthe-
sized in our laboratory, including [Ibull, D-Arg2, Phe(4-Cl)6, Abu"3,
Nle27] hGH-RH(1-28)Agm (MZ-4-71) (Zarandi et al, 1994). This
antagonist has previously been shown to inhibit growth of human
osteosarcomas (Pinski et al, 1995) and human small- and non-
small-cell lung cancers in athymic nude mice (Pinski et al, 1996).
In the present study, we investigated the effect of the GH-RH
antagonist MZ-4-71 on the growth of the hormone-independent
prostate cancer cell lines DU-145 and PC-3 xenografted into nude
mice, and rat Dunning R-3327 AT-1 tumours transplanted into
Copenhagen rats. In addition, we examined the effect ofthis antag-
onist on the proliferation of DU-145 and PC-3 cells in vitro.
MATERIALS AND METHODS
Peptide and reagents
The GH-RH antagonist MZ-4-71, ([Ibu'', D-Arg2, Phe(4-Cl)6,
Abu", Nle'7] hGH-RH(1-28)Agm) was synthesized by solid-
phase methods and purified in our laboratory (Zarandi et al, 1994).
For daily injections, MZ-4-71 was dissolved in 0.1I% dimethyl
sulphoxide (DMSO) in 10% propylene-glycol in saline solution.
Animals
Male athymic (NCr nu/nu) nude mice, approximately 6 weeks old
on arrival, were obtained from the National Cancer Institute
(Bethesda, MD, USA) and housed in laminar airflow cabinets
under pathogen-free conditions with a 12-h light/12-h dark
schedule and fed autoclaved standard chow and water ad libitum.
Their care was in accord with institutional guidelines. Copenhagen
male rats were obtained from Charles River Laboratories
(Frederick, MD, USA). They were housed four to a cage in a
temperature-controlled room with a 12-h light/12-h dark schedule
and fed water and standard rat chow ad libitum.
Cell culture
The human androgen-independent prostatic carcinoma lines
DU-145 and PC-3 were obtained from the American Type Culture
Collection (ATCC), Rockville, MD, USA. DU-145 and PC-3 cells
were grown as a monolayer in RPMI-1640 medium (Gibco, Grand
Island, NY, USA) supplemented with 10% and 5% fetal bovine
serum, respectively, antibiotics and antimycotics, at 37°C in a
humidified 95% air/ 5% carbon dioxide atmosphere. Tumourcells
growing exponentially were harvested by brief incubation with
0.25% trypsin-EDTA solution (Gibco). Xenografts of PC-3 and
DU-145 were initiated by subcutaneous (s.c.) injection of I x 107
cells into the left flanks of five male nude mice for each tumour
cell line.
Experimental protocol
Experiments I and 11
PC-3 and DU-145 tumours resulting after 8 weeks ofgrowth were
aseptically dissected and mechanically minced; 3-mm3 pieces of
each tumour tissue were transplanted s.c. by trocar needle into two
groups of 30 male animals under methoxyflurane (Metofane;
Pitman-Moore, Mundelein, IL, USA) anaesthesia. The tumour
take rate was 70% for DU-145 and 90% for PC-3 tumours. Three
weeks after transplantation, DU-145 or PC-3 tumours had grown
to a volume between 17 and 24 mm3. Mice bearing PC-3 or
DU-145 tumours were then divided in both experiments into two
groups of eight animals each. Control groups were injected only
with 0.1% DMSO in 10% propylene-glycol/saline, s.c.; and exper-
imental groups were treated with MZ-4-71, 20 .tg twice a day, s.c.
The treatment was continued for 6 weeks for DU-145 tumours and
for 4 weeks for PC-3 tumour-bearing nude mice. The tumours
were measured once a week with microcalipers, and the tumour
volume was calculated as length x width x height x 0.5236 (Janik
et al, 1975). Tumour volume doubling time was calculated
between the start and the end of the experiment. At the end of the
treatment period, mice were anaesthetized with methoxyflurane,
killed by decapitation and trunk blood was collected. The serum
was separated and frozen for further analyses. Body weights were
recorded and various organs were removed and weighed. Tumours
were carefully cleaned and weighed, and samples were taken for
receptor studies. Tumour samples and liver tissues were collected
for measurements oftissue levels of IGF-I and -II.
Experiment Ill
Dunning R-3327 AT-1 tumour-bearing rats were kindly provided
by Dr John T Isaacs (The Johns Hopkins Oncology Center,
Baltimore, MD, USA). The tumour was aseptically dissected and
mechanically minced; 3-mm3 pieces of tumour tissue were trans-
planted s.c. in the scapular region by trocar needle into five male
Copenhagen rats under methoxyflurane anaesthesia. Two weeks
after transplantation, tissue obtained from growing tumours was
transplanted subcutaneously into 20 male Copenhagen rats under
methoxyflurane anaesthesia. Treatment was started immediately
after tumour transplantation. The rats were divided into two
groups (ten rats per group): group I (control) received 0.1%
DMSO in 10% propylene-glycol/saline, i.p.; group 2 was injected
with 100 ,ug of MZ-4-71 per animal per day i.p., for 3 weeks. All
experiments were approved by the institutional ACUC and the
procedures were essentially in accordance with UKCCCR guide-
lines for the welfare of animals in experimental neoplasia.
Method of tissue extraction
Tumour and liver tissue concentrations of IGF-I and IGF-II were
determined by an adaptation of the methods described previously
(D'Ercole et al, 1984). The tissue was cut in small slices and
homogenized in 5 ml of I M acetic acid 1 g-I tissue using Ultra
Turrax homogenizer at 4°C. The homogenate was centrifuged at
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2000 xg for 20 min at 4°C. The supernatant was collected and the
pellet was washed and recentrifuged. The supernatants were
combined, lyophilized and reconstituted in 0.1 M phosphate buffer.
The BIO-RAD protein assay kit (Hercules, CA, USA) was used
for protein determination.
Radioimmunoassays of GH, IGF-I and IGF-II
Serum GH was determined using materials provided by Dr AF
Parlow (Pituitary Hormones and Antisera Center, Torrance, CA,
USA; mouse GH reference preparation AFP10783B, mouse GH
antigen AFP10783B and anti-rat GH-RIA-5/AFP-411S). All
serum and reconstituted tissue samples for IGF-I and IGF-II deter-
mination were extracted by amodified acid-ethanol cryoprecipita-
tion method described previously (Daughaday et al, 1980; Breier
et al, 1991). This method eliminates most of the IGF binding
proteins, which can interfere in the radioimmunoassay (RIA). The
extracted IGF-I was measured by RIA using IGF-I (88-G4, from
Genentech, San Francisco, CA, USA) for standard in the range of
2-500 pg per tube and for iodination using the standard chlor-
amine-T method. Antibody UB3-189 and UB2-495 (a gift from Dr
Underwood and J van Wyk) obtained from NIDDK was used at the
final dilution of 1:10 000 and 1:14 000 in the RIA.
IGF-II was measured using human recombinant IGF-II
(Bachem California, Torrance, CA, USA) in the range of2-500 pg
per tube. IGF-II was iodinated by lactoperoxidase method and
purified by reverse-phase high-performance liquid chromatog-
raphy (HPLC) using a Vydac C18 column. For the assay, Amano
monoclonal antibody generated against rat IGF-II (10 ,ug ml-') was
used at a final dilution of 1:14 285 (Amano Enzymes USA, Troy,
VA, USA). This antibody cross-reacts 100% with human and rat
IGF-II and 10% with human IGF-I (Tanaka et al, 1989).
Receptor assay
Measurement ofreceptors for IGF-I in the membranes ofDU-145,
PC-3 and Dunning R-3327 AT-1 tumours was performed as
described previously (Pinski et al, 1995). The LIGAND PC
computerized curve-fitting program of Munson and Rodbard
(1980) was used to determine the types ofreceptor binding, disso-
ciation constant (Kd) values and the maximal binding capacity
(Bmax) ofreceptors.
Growth in serum-free medium
For the MTT assay, cells were seeded into 96-well microplates
(Falcon, Lincoln Park, NJ, USA) in serum-free medium. The
medium contained RPMI-1640 (Gibco), 0.5% bovine serum
albumin (BSA), 1 mm pyruvate and 1 ,UM ferrous sulphate (all
from Sigma).
MTT assay
This assay is based on a method described by Plumb et al (1989).
Briefly, cells were seeded into 96-well microplates and cultured
for 18 h. MZ-4-71 was added to the medium in final concentra-
tions of 10-7-10-5 M. Control cultures received serum-free medium
alone. After 72 h of culture, the medium was removed and 200 gl
of serum-free medium containing 80 ,ug of MTT [3,(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide; Sigma]
was added. The microplates were incubated for 4 h at 37°C in
darkness. The medium was removed, cells were washed with
RPMI-1640 medium, then 200 jl ofdimethyl sulphoxide (DMSO;
Sigma) was added, followed by 25 jil ofSorensen's glycine buffer
(0.1 M glycine plus 0.1 M sodium chloride, pH 10.5). After a brief
mixing, the plates were read at 540 nm on the plate reader
(Beckman, Palo Alto, CA, USA). Results were calculated as
% TIC, where T = optical density (OD540nm) of treated cultures
(serum-free medium plus MZ-4-71) and C = OD540nm of control
cultures (serum-free medium alone) x 100.
Statistical methods
All data are expressed as means ± s.e.m., and statistical analyses of
the tumour data were performed using Duncan's new multiple
range test (Steel and Torrie, 1976). All P-values are based on two-
sided hypothesis testing.
RESULTS
Effects of GH-RH antagonist MZ-4-71 on growth of
DU-145 and PC-3 tumours in nude mice
At the end of the experiments, there were no significant differ-
ences in body weights between the treated and the untreated
groups except that mice with PC-3 tumours, given MZ-4-71,
weighed more than the control animals (Table 1). In experiment I,
after 4 weeks of treatment, the volume of DU-145 prostate
carcinomas in the group receiving MZ-4-71 was significantly
reduced to 30.9 ± 11.1 mm3 compared with the control group
(91.2 ± 12.3 mm3), corresponding to a 66% decrease in tumour
volume (Figure lA). After 6 weeks, the final tumour volume and
weight were significantly (P < 0.01) diminished in animals treated
with MZ-4-71 to 37.6 ± 13.5 mm3 and 4.0 ± 1.0 mg, respectively,
compared with controls (194.2 ± 55.4 mm3 and 18.6 ± 3.0 mg).
Tumour doubling time in mice receiving MZ-4-71 was extended to
56.6 days from 13.4 days calculated for control animals.
In experiment II, therapy with MZ-4-71 also inhibited the
growth of PC-3 prostate cancer tumours (Figure IB). After
4 weeks of therapy, when the experiment was terminated, mean
tumour volume and weight were significantly (P < 0.01) reduced
in animals receiving GH-RH antagonist MZ-4-71 to 119.9 ± 35.3
mm3 and 13.1 ± 3.6 mg compared with those for control animals,
which were 397.5 ± 115.6 mm3 and 56.1 ± 8.6 mg respectively.
Tumour doubling time was prolonged by MZ-4-71 to 17.8 ± 3
days from 8.7 ± 1.3 days found for control animals (P < 0.05).
Effect of GH-RH antagonist MZ-4-71 on Dunning R-3327
AT-1 tumours in rats
In experiment III, MZ-4-71 effectively suppressed growth of
the very fast proliferating Dunning R-3327 AT-I tumour in rats.
After 3 weeks of therapy, tumour volume was 6153 ± 1267 mm3
in the group treated with GH-RH antagonist compared with
11 005 ± 1338 mm3 for control animals (P < 0.05) (Figure 2).
The therapy with MZ-4-71 also significantly reduced tumour
weight but did not affect body weight. The effects ofthe treatment
on final tumour volume, body and tumour weight and tumour
doubling time for rats bearing Dunning R-3327 AT-1 prostate
carcinoma are shown in Table 1.
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Figure 1 Tumour volumes in athymic nude mice bearng subcutaneously
xenografted DU-145 (A) and PC-3 (B) human prostate carcinomas during
treatment with the growth hormone-releasing hormone antagonist MZ-4-71
administered at a dose of 20 gg twice a day, s.c. Treatment was started when
the tumours measured approximately 17-24 mm3 and lasted for 6 and 4
weeks respectively. Vertical bars represent standard error; P < 0.05 vs
control; **P< 0.01 vs control
Effect of MZ-4-71 on serum and tissue IGF-1, IGF-11 and
serum GH levels
The serum levels of GH and IGF-I in control animals and in nude
mice treated with the peptide analogue are shown in Table 2. In
DU-145 tumour-bearing mice, serum GH levels were significantly
reduced in the group treated with MZ-4-71 to 3.61 ± 0.29 ng ml-',
0
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Figure 2 Tumour volumes in male Copenhagen rats bearing subcutaneously
transplanted rat Dunning R-3327-AT-1 prostate carcinoma during treatment
with the GH-RH antagonist MZ-4-71 administered intraperitoneally (i.p.) at a
dose of 100 iggper animal perday. Treatment was started immediately after
tumour transplantation and lasted for 3 weeks. Vertical bars represent
standard error; *P< 0.05 vs control
compared with control animals (21.27 ± 5.34 ng ml-'). The
GH-RH antagonist also significantly decreased serum IGF-I levels
to 134.5 ± 0.7 ng ml-', compared with 172.5 ± 1 ng ml-' in control
animals. Serum levels ofIGF-ll at the end ofthe treatment period
with MZ-4-71 were similar to those in control animals (Table 2).
In animals bearing PC-3 tumours, serum growth hormone was
decreased by 46% in the MZ-4-71-treated group (31.1 ± 1.9 ng
ml-' vs 57.1 ± 3.6 ng ml-' for control animals; P < 0.05). Serum
IGF-I was also significantly lower in the animals treated
with GH-RH antagonist (93.8 ± 13.6 ng ml-') compared with
135.6 ± 10.6 ng ml-' for control animals, whereas serum IGF-II
levels were similar (Table 2). Therapy with MZ-4-71 reduced the
IGF-I and IGF-II concentrations in PC-3 tumour tissue below
the detection range of the relevant RIA, whereas control tumour
tissue showed 145.36 ± 25.22 pg IGF-I 100 jg-' protein and
189.11 ± 31.44 pgIGF-ll 100 .g-' protein (Table 3). Aftertherapy
with MZ-4-71, levels ofIGF-II in livertissue ofnude micebearing
PC-3 tumours were not significantly changed, while those of
IGF-I were reduced from 44.58 ± 4.5 to 32.55 ± 2.5 pg 100 jig-'
protein (P < 0.05)(Table 3). IGF-I and IGF-II measurements in rat
serum from the animals implanted with Dunning R-3327AT-1
tumours could not be performed because of an accidental loss of
samples.
Effect of GH-RH antagonist MZ-4-71 on IGF-I receptors
of various tumour models
The binding characteristics of receptors for IGF-I in the
membranes DU-145, PC-3 and Dunning R-3327-AT-1 tumours
were analysed following treatment with GH-RH antagonist
MZ-4-71 and the results are presented in Table 4. High-affinity
binding sites for IGF were present in the membranes of DU-145
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Table 1 Effect of treatment with GH-RH antagonist MZ-4-71 on tumour volume, body and tumour weight, and tumour doubling time in nude mice bearing
xenografts of the human prostate cancer cell lines DU-145 and PC-3 and in rats bearing transplanted Dunning R-3327-AT-1 tumours
Treatment Tumour volume (mm3) Body weight Tumour weight Tumour doubling time
group (g) (mg) (days)
Initial Final
DU-145
Control 22.3 ± 4.1 194.2 ± 35.4 34.0 ± 1.0 18.6 ± 3 13.4 ± 2.6
MZ-4-71 24.2 ± 0.8 37.6 ± 13.5a 32.0 ± 1.0 4.0±1 a 56.6± 12.2b
PC-3
Control 17.7 ±2.8 397.5 ± 115.6 29.7 ± 0.7 56.1 ± 8.6 8.7± 1.3
MZ-4-71 17.8 ± 3.8 119.9 ± 35.3a 35.3 ± 0.9b 13.1 ± 3.6a 17.8 ± 3.0b
Dunning R-3327-AT-1
Control 3± 1 11005 ± 1388 385 ± 17 7500 ±600 1.77 ± 0.8
MZ-4-71 3 ± 1 6153± 1267b 392 ± 11 5500±900b 1.91 ± 0.3
Values are means ± s.e. ap< 0.01 vs control. bp< 0.05 vs control.
Table 2 Serum GH, IGF-I and IGF-Il levels in athymic nude mice bearing
DU-145 and PC-3 human prostate cancer cell line xenografts after treatment
with GH-RH antagonist MZ-4-71
Treatment Growth hormone (GH) IGF-I IGF-11
group (ng ml-') (ng ml-') (ng ml-')
DU-145
Control 21.27 ± 5.34 172.5 ± 1.0 25.1 ±2.9
MZ-4-71 3.61 ±0.29a 134.5 ± 0.7b 21.9 ± 2.2
PC-3
Control 57.1 ± 3.6 135.6 ± 10.6 24.8 ± 1.6
MZ-4-71 31.1 ± 1.9a 93.8 ± 13.6b 25.6 ± 0.5
Values are means ± s.e. ap< 0.01 vs control. bp< 0.05 vs control.
tumours (Kd = 0.82 ± 0.11 nM). A significant (P < 0.01) increase in
binding capacity of IGF-I receptors was observed after treatment
with MZ-4-71 (Bmax = 244.6+ 4.9 fmol mg-' membrane protein vs
151.4 ± 5.85 fmol mg-' membrane protein for control animals)
(Table 4).
In PC-3 tumour membranes, specific high-affinity binding sites
for IGF were also demonstrated. In control tumours, the dissocia-
tion constant was calculated to be Kd = 0.69 ± 0.25 nm and
maximal binding capacity Bmax = 90.6 ± 12.9 fmol mg-' membrane
protein. Aftertherapy with MZ-4-71, Bmax ofthe receptors forIGF-
I was significantly augmented; i.e. the number of high-affinity
receptor sites was increased to 164.4 ± 3.8 fmol mg-1 membrane
protein (Table 4).
Receptor assays on control rat Dunning R-3327-AT-1 tumours
showed high-affinity binding sites for IGF-I (Kd = 0.49 ± 0.14 nM).
After 3 weeks of treatment with MZ-4-71, there were no signifi-
cant changes in the concentration and the affinity of the receptors
for IGF-I.
Effects of IGF-I and GH-RH antagonist MZ-4-71 on cell
proliferation in vitro
In order to evaluate the stimulatory effect of IGF-I and a possible
anti-proliferative activity of the GH-RH antagonist MZ-4-71 on
DU-145 and PC-3 cell lines in vitro, the MTT assay was used.
However, IGF-I at concentrations of 5-25 ng ml-l did not signifi-
cantly stimulate the proliferation of either cell line and the
stimulation was calculated to be only between 8% and 23%.
At a relatively high concentration of 10-5 M, GH-RH antagonist
MZ-4-71 decreased the proliferation of DU-145 cells by 63.3%
compared with the control (P < 0.05), but lower concentrations of
the antagonist only non-significantly blunted growth of DU-145
cells. The PC-3 prostate cancer cell line was not affected by
MZ-4-71, even at concentrations up to I0-5 M (data not shown).
DISCUSSION
There are few therapeutic options available for the therapy of
androgen-independent prostate carcinoma. Suramin, a poly-
sulphonatednaphthylurea, primarily usedin thetreatmentofparasitic
disorders, produces a clinical response rate of approximately 50%
in patients with advanced, androgen-independent prostate cancers
(Eisenberger et al, 1993). The actual mechanism of anti-tumour
Table 3 Tumour and liver IGF-I and IGF-Il levels in athymic nude mice bearing PC-3 xenografts after
treatment with the GH-RH antagonist MZ-4-71
Treatment group Tumour Liver
IGF-I IGF-11 IGF-I IGF-11
(pg 100 gg-' protein) (pg 100,g-' protein)
Control 145.36 ± 25.22 189.11 ± 31.44 44.58 ± 4.5 33.82 ± 6.1
MZ-4-71 ND ND 32.55 ± 2.578 28.36 ± 3.1
All values are means ± s.e. ap < 0.05. ND, . not detectable.
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Table 4 Binding characteristics of receptors for IGF-I in membranes of DU-
145, PC-3 and Dunning R-3327-AT-1 prostate carcinomas after in vivo
treatment with GH-RH antagonist MZ-4-71
Treatment K B. d max
group (nM) (fmol mg-' membrane protein)
DU-145
Control 0.82+ 0.11 151.4 ± 5.85
MZ-4-71 0.78 ± 0.1 244.6 ± 4.9a
PC-3
Control 0.69 + 0.25 90.6 + 12.9
MZ-4-71 0.87 + 0.13 164.4 ± 3.8b
Dunning R-3327-AT-1
Control 0.49 ± 0.14 71.4 ± 8.9
MZ-4-71 0.80 + 0.08 100.3 + 3.6
Binding characteristics were obtained from ten-point displacement
experiments. Significance was calculated with Duncan's new multiple range
test. All values represent means ± s.e. of 2-3 experiments, each done in
triplicate. ap< 0.01 vs control. bp< 0.05 vs control.
activity of this drug is unknown, but inhibition of binding of
various growth factors to their receptors has been suggested as a
possibility. Pollak and Richard (1990) blocked the IGF-I-stimu-
lated proliferation of human osteosarcoma cells with suramin,
reinforcing the hypothesis of the possible importance of the
GH-IGF-I axis in tumour growth stimulation. Human DU-145 and
PC-3 prostate cancer cell lines and rat Dunning R-3327 AT-1
prostate carcinoma are suitable models ofthe advanced, hormone-
insensitive stage of this malignant disease. Our work shows that
GH-RH antagonist MZ-4-71 effectively inhibits the growth of
DU-145 and PC-3 prostate cancer in nude mice and prolongs
tumour doubling time. Our findings on this GH-RH antagonist are
in accordance with previous studies on osteosarcoma cell lines
(Pinski et al, 1995) and human small-cell and non-small-cell lung
carcinomas (Pinski et al, 1996), in which MZ-4-71 effectively
inhibited tumour growth.
GH receptors have been identified in a large number oftissues,
among them the human prostate and PC-3 prostate cancer cell line
(Reiter et al, 1995). Treatment with MZ-4-71 significantly
reduced serum GH levels in nude mice bearing DU-145 or PC-3
prostate carcinomas. This suggests that some of the inhibitory
effect of the GH-RH antagonist might be attributed to the reduc-
tion in serum GH concentration. GH directly regulates the IGF-I
synthesis in the liver and other organs (Macaulay, 1992). A signif-
icant fall in GH levels, induced by the GH-RH antagonists, could,
through mechanisms involving suppression of IGFs, be of major
importance for the inhibition oftumour growth. Measurements of
serum IGF levels can be affected by the presence of IGF-binding
proteins, but our assays were performed after acid-ethanol cryo-
precipitation extraction (Breier et al, 1991; Daughaday et al,
1980). Recently, Lee et al (1996) examined acid-ethanol extrac-
tion and acid-chromatography procedure for IGF and reported
that the results were nearly identical. Only small amounts of
residual small molecular weight IGF-binding proteins were found
in the acid-ethanol extraction (Lee et al, 1996). Crawford et al
(1992) also compared various extraction methods for IGF-I in rat
serum, including acid-ethanol extraction with HPLC method.
Their results show that IGF-I levels found after acid-ethanol
extraction are similar to those obtained by HPLC. Crawford et al
(1992) also indicated that the acid-ethanol extraction method of
Daughaday et al (1980), originally validated for human serum, is
also satisfactory for use with rat serum. Our work shows that, in
nude mice treated with the GH-RH antagonist MZ-4-71, serum
IGF-I levels were significantly lower compared with control
animals. There are conflicting data about the role of the IGF
system in the biology ofDU-145 and PC-3 human prostate cancer
cell lines. Pietrzkowski et al (1993) have reported that DU-145
and PC-3 cells maintain an autocrine production of IGF-I. They
showed that the concentration ofautocrine IGF-I was sufficient to
autophosphorylate the IGF-I receptor and to sustain growth in
serum-free cell culture conditions. This autocrine loop, in which
produced IGF-I activates its receptors, is at variance with a study
by Iwamura et al (1993), who found IGF-I receptors in both cell
lines, but could not detect autocrine production of IGF-I.
Similarly, Figueroa et al (1995) and Angelloz-Nicoud and Binoux
(1995) found an expression of IGF-II and IGF receptors in DU-
145 and PC-3 prostate cancer cells respectively, but failed to
detect mRNA for IGF-I. Their data suggest an IGF-II-dependent
autocrine growth loop.
In our in vitro experiments, addition of 5-25 ng ml-' IGF-I had
no stimulatory effect on proliferation in DU-145 and PC-3 cell
lines. This is in accord with Pietrzkowski et al (1993), who
showed that substantial amounts of IGF-I are secreted by the
respective cell lines into the medium and that further exogenous
IGF-I had no additional effect on cell proliferation. The determina-
tion of GH-RH and GH receptors in prostate cancer and other
tumours is the subject of our ongoing investigations. The lack of a
dose-dependent effect of GH-RH antagonist MZ-4-71 on the
proliferation of DU-145 and PC-3 prostate cancer cells in vitro
suggests that no receptors for GH-RH were present on the
membranes of these cells or that these cell lines could have
undergone changes in GH-RH receptor content during long-term
passages in cell cultures. Examples ofthe loss ofpeptide receptors
after multiple passages are well known (Pinski et al, 1994). Thus,
in a study on human colonic and gastric tumour cells, Watson et al
(1988) found that the newly established cell lines were stimulated
by pentagastrin at passage 2, butlong-established cell lines did not
respond to pentagastrin, indicating that tumour cell response to
hormones was decreased or lost during in vitro cultures. These
phenomena might explain the differences between the extent of
tumour growth inhibition in vivo and in vitro obtained with our
peptides. The doses of MZ-4-71 used in vitro to achieve an inhibi-
tion of proliferation of DU-145 tumours were very high. The
concentration of MZ-4-71 in the blood of nude mice given a
subcutaneous injection of this antagonist at a dose of 20 gg per
animal is approximately 20 pM (Pinski et al, 1995), i.e. 500 000
times lower than the dose of MZ-4-71 required to inhibit the
growth of DU-145 cells in vitro (10 gM). It would also be
intriguing to speculate whether a possible relationship might exist
between GH and GH-RH receptors and IGF-I and IGF-II produc-
tion in tumours, since both these growth factors appear to be
involved in PC-3 and DU-145 cell proliferation (Pietrzkowski et
al, 1993; Angelloz-Nicoud and Binoux, 1995; Figueroa et al,
1995). However, in the absence of this information, the inhibitory
effect of MZ-4-7 1 on the growth of androgen-independent
prostatic cancers in vivo observed in our study may be attributed
to the suppression of pituitary GH and hepatic IGF-I secretion and
only tentatively to unknown mechanisms leading to an inhibition
of autocrine/paracrine IGF-I and IGF-II production and/or
lowering of tumour IGF-I and IGF-II levels.
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In our study, tissue concentrations of IGF-I and -II were
measured in the liver and tumours of treated and untreated PC-3
tumour-bearing animals. In the liver, IGF-I levels were signifi-
cantly blunted in the MZ-4-71-treated group, whereas IGF-II
levels did not change. On the other hand, in PC-3 tumours, both
IGF-I and IGF-1I fell below the detection range of the specific
RIAs after the treatment with MZ-4-7 1.
Our findings, which show the presence of high-affinity binding
sites for IGF-I in membranes of both PC-3 and DU-145 tumours,
are in agreement with results previously reported by other groups
(Pietrzkowski et al, 1993; Iwamura et al, 1993; Figueroa et al,
1995). IGF-I and IGF-II bind with different affinities to type 1 IGF
receptor, which is thought to mediate the biological effects ofboth
ligands through tyrosine kinase-type activity (Cohen et al, 1994).
We observed that chronic treatment of nude mice with the GH-RH
antagonists produced an increase of the concentration of IGF-I
receptors on both tumours. This phenomenon might be an indica-
tion of a compensatory up-regulation of IGF-I receptor synthesis
caused by suppression ofthe endocrine or local production ofIGF-I.
Dunning R-3327 AT-I is a fast growing anaplastic, androgen-
independent rat prostate cancer derived from the rat Dunning-H
tumour (Isaacs et al, 1978). In this model, the tumour growth was
also decreased in the GH-RH antagonist-treated group. The mech-
anism of action of GH-RH antagonist in this prostate cancer is
unclear. It has been demonstrated that Dunning R-3327 tumours
express GH receptors (Sinowatz et al, 1991). Thus, the decrease in
the levels of GH could contribute to the inhibition of tumours.
Tumour growth suppression could also be caused by inhibition of
IGF-I levels, since Kovacs et al (1996) showed that chronic admin-
istration of MZ-4-7 1 reduces serum IGF-I concentration in rats by
15%. High-affinity receptors for IGF-I were demonstrated in
membranes of Dunning R-3327 AT-I tumours, but chronic treat-
ment of rats with the GH-RH antagonist did not produce a signifi-
cant increase ofthe concentration of IGF-I receptors.
Our study shows that, in androgen-independent prostate cancer
models, GH-RH antagonist MZ-4-71 can inhibit tumour growth
and reduce serum IGF-I levels. Moreover, tumour tissue IGF-I and
-II concentrations were decreased in the human PC-3 and DU-145
cell lines. Ifsimilar effects can be achieved in men, GH-RH antag-
onists might be considered for the development ofnew approaches
to the treatment of patients with prostatic carcinoma who have
relapsed following conventional androgen deprivation treatment.
ABBREVIATIONS
GH, growth hormone; GH-RH, growth hormone-releasing
hormone; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like
growth factor-II; IGFR, insulin-like growth factor receptor; EGF,
epidermal growth factor; LH-RH, luteinizing hormone-releasing
hormone; TGF-a and -3, transforming growth factor-oc and -,B;
DMSO: dimethyl sulphoxide.
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